Mangrove Partners Mereo Biopharma Group PLC Call Options Transaction History
Mangrove Partners
- $936 Million
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MREO
# of Institutions
88Shares Held
85.6MCall Options Held
182KPut Options Held
249K-
Rubric Capital Management LP New York, NY13.6MShares$46.8 Million1.52% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.33MShares$32.2 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD8.14MShares$28.1 Million0.7% of portfolio
-
683 Capital Management, LLC New York, NY5.75MShares$19.8 Million1.62% of portfolio
-
Janus Henderson Group PLC London, X05.12MShares$17.7 Million0.01% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $431M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...